* Cel-Sci Corp. of Vienna, Va., reported that different formulations of its HGP-30 AIDS vaccine elicited significant delayed-type hypersensitivity and T-cell proliferation responses in mice. Those responses are strong indicators of the induction of cellular immune responses, which some scientists consider essential for an effective AIDS vaccine. HGP-30 W (an improved version of HGP-30) is in a Phase II trial in Europe.

* CoCensys Inc., of Irvine, Calif., implemented a new business model with three business drivers to enhance shareholder value - technology, the ability to provide product development services to its product licensees, and the ability to provide product development services to a niche, undeserved segment of the contract research organization market. CoCensys plans to form strategic business alliances with companies whose technologies are poised for development but seeking to augment their own internal development capabilities.

No Comments